Vir Biotechnology 거래 VIR

매도
 매수

VirBiotechnology 실시간 차트

5m 15m 30m 1h 4h 1d 1w

상품 기초

Weekly Search
Weekly
Daily
날짜 종료 변경 변동(%) 열기 높음 낮음

VirBiotechnology news

number1 2025 Jul 11, 03:38

AI Podcast: Dollar Weakness and Investment Implications

number1 2025 Jul 11, 03:38

HSBC: Three 'Painful Trade' Risks Loom if Wall Street Gets It Wrong

number1 2025 Jul 11, 03:38

Turkey's $500 Billion Gold Hoard: Unlocking Economic Potential

number1 2025 Jul 11, 03:37

Brazil-US Tariffs: Trump's Intervention and Lula's Response

number1 2025 Jul 11, 00:00

AI Podcast: US & Israel's Disagreements on Iran and Gaza

최신 뉴스

더 보기
number1 2025 Oct 21, 00:00

Zelenskyy Expresses Doubts About Budapest as Venue for Ukraine Peace Talks

number1 2025 Oct 21, 00:00

Europe Rallies Behind Ukraine Amid Trump Pressure, Eyes Frozen Russian Assets

number1 2025 Oct 21, 00:00

US Government Shutdown: Economic Fallout and Political Impasse

number1 2025 Oct 21, 00:00

Gold Price Surge Fueled by Fed Rate Cut Expectations and Economic Uncertainty

number1 2025 Oct 19, 00:00

Global Market Overview: Precious Metals Surge Amidst Economic Uncertainty

number1 2025 Oct 18, 00:00

Japan LDP-Ishin Policy Talks: Paving the Way for a New Prime Minister?

number1 2025 Oct 18, 00:00

Israel Prepares to Reopen Rafah Crossing Amid Ceasefire Violation Claims

number1 2025 Oct 18, 00:00

Fed's Rate Cut Conundrum: An Outlook to 2026

정보

스프레드

0.05

스프레드(%)

0.6748 %

레버리지

1:10

익일 이자 매수

-0.0597 %

익일 이자 매도

-0.0292 %

통화

USD

거래 시간

시장 폐장

목요일

14:31 - 20:59

화요일

14:31-20:59

수요일

14:31-20:59

금요일

14:31-20:59

분석 및 통계

열기

---

이전 종가

---

52주 최고/최저

--- – ---

시가총액

1412732672

발행 주식 수

159811395

수익 날짜 (다음)

0000-00-00

배당수익률

배당락일

예상 연간 배당금

0

예상 연간 배당수익률

0

EPS

-3.16

이 상품에 대해 자세히 알아보기

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

관련 상품

자산
매도
매수
변동(%)

지금 거래하기

지금 거래하기

지금 거래하기

지금 거래하기
view_all_instruments

latest_education_articles

더 보기
Frances Wang 2025 Feb 17, 16:00

Pi network price prediction 2025: Will Pi Network price go up or down?

Stocks
Frances Wang 2025 Jan 21, 16:00

What is the XRP price prediction for 2025: Will XRP reach $1000?

Crypto
Frances Wang 2024 Dec 29, 16:00

What is the USD DXY index and how does the DXY reflect the dollar's value?

Indices
Trustpilot